Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Current Oncology (Toronto, Ont.)
|
July 28, 2023
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research
Ritesh Kumar, Jongmyung Kim, Matthew P Deek, et al.
Cancer Medicine
|
January 8, 2024
Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials
Emma Vail, Ankur P Choubey, H Richard Alexander, et al.
Journal of Gastrointestinal Oncology
|
January 24, 2022
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
Shane S Neibart, Swati Mamidanna, Anupama Chundury, et al.
JAMA Network Open
|
February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Annals of Surgical Oncology
|
May 22, 2025
Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases
Vasileios Tsagkalidis, Elizabeth A Handorf, Benjamin A Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
Cancer Medicine
|
August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer
Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Advanced Biology
|
March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Mojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Current Oncology (Toronto, Ont.)
|
July 28, 2023
Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research
Ritesh Kumar, Jongmyung Kim, Matthew P Deek, et al.
Cancer Medicine
|
January 8, 2024
Recurrence-free survival dynamics following adjuvant chemotherapy for resected colorectal cancer: A systematic review of randomized controlled trials
Emma Vail, Ankur P Choubey, H Richard Alexander, et al.
Journal of Gastrointestinal Oncology
|
January 24, 2022
Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy
Shane S Neibart, Swati Mamidanna, Anupama Chundury, et al.
JAMA Network Open
|
February 18, 2022
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial
Niharika B Mettu, Fang-Shu Ou, Tyler J Zemla, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2023
Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164
Dung T Le, Luis A Diaz, Tae Won Kim, et al.
Annals of Surgical Oncology
|
May 22, 2025
Estimating the Survival Impact of Curative-Intent Liver Therapies for Colorectal Cancer Liver Metastases
Vasileios Tsagkalidis, Elizabeth A Handorf, Benjamin A Bates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, et al.
Cancer Medicine
|
August 29, 2025
Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer
Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 15, 2019
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T Le, Tae Won Kim, Eric Van Cutsem, et al.
Advanced Biology
|
March 28, 2022
Understanding Suboptimal Response to Immune Checkpoint Inhibitors
Mojun Zhu, Henan Zhang, Katrina S Pedersen, et al.
Page
of 5